Better Outcomes? Tenecteplase Before Late Stroke EVT
Tenecteplase before EVT represents a developing frontier in acute stroke management. Historically, physicians limited thrombolytic use to the early 4.5-hour window. However, the TNK-PLUS trial recently investigated this therapy in patients presenting 4.5 to 24 hours after onset. This multicenter study focused on middle cerebral artery occlusions with salvageable brain tissue. Consequently, the results offer important guidance for interventionalists in India who manage complex stroke cases.
Efficacy of Tenecteplase before EVT
Researchers conducted this phase 3 trial across forty centers in China. They randomly assigned patients to receive either tenecteplase or a placebo before mechanical thrombectomy. Specifically, the experimental group received a 0.25 mg/kg dose of the drug. Furthermore, the team assessed functional independence at ninety days using the modified Rankin Scale. Interestingly, the data showed no significant improvement in disability outcomes for the tenecteplase group compared to the control group.
Safety and Clinical Implications
Although the primary endpoint did not show superiority, safety outcomes remained consistent between groups. For instance, the incidence of symptomatic intracranial hemorrhage did not rise significantly. Additionally, the tenecteplase group exhibited higher rates of early reperfusion before the start of the procedure. Therefore, clinicians must weigh these nuanced benefits against the lack of overall functional improvement. Future protocols might refine patient selection to identify those who benefit most from this bridging approach.
Frequently Asked Questions
Q1: What was the primary finding of the TNK-PLUS trial regarding Tenecteplase before EVT?
The trial found that administering tenecteplase before endovascular treatment in the 4.5 to 24-hour window did not significantly improve functional outcomes at 90 days compared to endovascular treatment alone.
Q2: Did tenecteplase increase the risk of brain bleeding in this study?
No, the study reported that the incidence of symptomatic intracranial hemorrhage was similar between the tenecteplase group and the placebo group, suggesting a stable safety profile.
Q3: Was there any benefit observed in the tenecteplase group?
The tenecteplase group showed a higher rate of successful vascular reperfusion before the mechanical thrombectomy procedure began, although this did not translate into better clinical recovery.
References
- Xiong Y et al. Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial. JAMA. 2026 May 08. doi: 10.1001/jama.2026.4292. PMID: 42099212.
- Campbell BCV, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018;378(17):1573-1582.
- Powers WJ, et al. 2019 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418.